Precision Biosciences ( (DTIL) ) has released its Q2 earnings. Here is a breakdown of the information Precision Biosciences presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Precision BioSciences, Inc., a biotechnology company specializing in gene editing technologies, focuses on developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. In its latest earnings report for the quarter ending June 30, 2025, Precision BioSciences reported a significant net loss of $23.5 million, a notable decline from the $32.7 million net income reported in the same quarter of the previous year. The company’s revenue also saw a sharp decrease, with only $18,000 reported for the quarter compared to $49.9 million in the previous year. This downturn is attributed to the termination of certain agreements and a strategic shift to focus solely on in vivo gene editing therapies. Despite the financial challenges, the company continues to invest in research and development, with expenses totaling $12.8 million for the quarter. Looking ahead, Precision BioSciences remains committed to advancing its ARCUS platform and exploring new collaborations to support its strategic focus on gene editing therapies.